A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies.
Thyroid Cancer
DRUG: AMG 706
Objective Response Rate (complete response and partial response) as defined by modified RECIST
Duration of response|Progression Free Survival|Changes in tumor markers|overall survival time|time to response|Tumour Related Symptoms (medullary thyroid cancer arm)|AMG 706 pharmacokinetic profile|patient reported outcome (EQ-5D)|Safety Endpoint: Incidence of treatment-emergent adverse events (including all, serious, treatment-related, and each by maximum severity).|Pharmacokinetic Enpoint: AMG 706 pharmacokinetic parameters (Cmax, t1/2, AUC0-24,C24)
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies.